Table 3.
Study | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting |
---|---|---|---|---|---|---|
Babkoff 2002 | U | U | H | L | H | L |
Bjorvatn 2007 | U | U | U | U | H | L |
Bjorvatn 2020 | U | L | L | U | H | L |
Boivin 2012 | U | U | U | U | L | H |
Comtet 2019 | L | U | U | U | L | L |
Dawson 1991 | U | U | U | U | L | L |
Dawson 1995 | U | U | L | U | L | L |
Griepentrog 2018 | H | U | U | U | L | L |
Horowitz 2001 | U | U | U | U | L | L |
Karchani 2011 | U | U | U | U | L | L |
Kretschmer 2013 | U | U | U | U | L | L |
Lee 2006 | U | U | U | U | L | L |
Lee 2020 | U | U | U | U | L | L |
Lowden 2004 | U | U | H | U | L | L |
Nagashima 2017 | U | U | U | U | L | L |
Sadeghniiat-Haghighi 2011 | U | U | U | U | L | L |
Smith 2009 | U | U | U | L | L | L |
Sunde 2020 | U | U | U | U | H | L |
Tanaka 2011 | L | L | H | U | L | L |
Thorne 2010 | U | U | H | U | H | L |
Yoon 2002 | U | U | U | U | L | L |
L low risk, H high risk, U unclear risk.